Build Your Comparison

Side-by-side financial analysis
AMGN logo
AMGN
BIIB logo
BIIB
Try popular comparisons:

Stock Comparison

AMGN vs BIIB

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals30-year financialsFull price history
AMGN
Amgen Inc.

Big Pharma

HealthcareNASDAQ • US
Market Cap$252.08B
5Y Perf.+110.3%
BIIB
Biogen Inc.

Neuroscience Biotech

HealthcareNASDAQ • US
Market Cap$37.01B
5Y Perf.+4.3%

AMGN vs BIIB — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
AMGN logoAMGN
BIIB logoBIIB
IndustryBig PharmaNeuroscience Biotech
Market Cap$252.08B$37.01B
Revenue (TTM)$38.93B$10.30B
Net Income (TTM)$9.39B$348M
Gross Margin74.0%70.0%
Operating Margin35.5%7.6%
Forward P/E19.9x20.1x
Total Debt$54.60B$6.95B
Cash & Equiv.$9.13B$3.01B

AMGN vs BIIB — Long-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

AMGN
BIIB
StockNov 20Nov 26Return
Amgen Inc. (AMGN)100210.3+110.3%
Biogen Inc. (BIIB)100104.3+4.3%

Price return only. Dividends and distributions are not included.

Quick Verdict: AMGN vs BIIB

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: AMGN leads in 5 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. Biogen Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
🥇AMGN emerged as the overall leader. Track its performance:
AMGN
Amgen Inc.
The Income Pick

AMGN carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • Dividend streak 15 yrs, beta 0.50, yield 2.0%
  • Rev growth 9.9%, EPS growth 88.2%, 3Y rev CAGR 11.8%
  • 268.5% 10Y total return vs BIIB's -22.1%
Best for: income & stability and growth exposure
BIIB
Biogen Inc.
The Defensive Pick

BIIB is the clearest fit if your priority is sleep-well-at-night and defensive.

  • Lower volatility, beta 0.35, Low D/E 38.1%, current ratio 2.68x
  • Beta 0.35, current ratio 2.68x
  • Beta 0.35 vs AMGN's 0.50, lower leverage
Best for: sleep-well-at-night and defensive
See the full category breakdown
CategoryWinnerWhy
GrowthAMGN logoAMGN9.9% revenue growth vs BIIB's 1.4%
ValueAMGN logoAMGNLower P/E (19.6x vs 19.9x)
Quality / MarginsAMGN logoAMGN24.1% margin vs BIIB's 3.4%
Stability / SafetyBIIB logoBIIBBeta 0.35 vs AMGN's 0.50, lower leverage
DividendsAMGN logoAMGN2.0% yield; 15-year raise streak; the other pay no meaningful dividend
Momentum (1Y)BIIB logoBIIB+55.1% vs AMGN's +41.8%
Efficiency (ROA)AMGN logoAMGN10.0% ROA vs BIIB's 1.1%, ROIC 14.8% vs 6.5%

AMGN vs BIIB — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

Discover the Biotech & Healthcare Stocks Theme

These companies are key players in the Biotech & Healthcare Stocks ecosystem. See how they stack up against the rest of the sector.

Explore Theme
AMGNAmgen Inc.
FY 2025
Other Products
20.6%$7.3B
Prolia
12.5%$4.4B
Repatha
8.5%$3.0B
Otezla
6.4%$2.3B
ENBREL
6.3%$2.2B
EVENITY
5.9%$2.1B
XGEVA
5.9%$2.1B
Other (8)
33.9%$12.0B
BIIBBiogen Inc.
FY 2025
MS Product Revenues
42.0%$4.0B
TYSABRI product
17.3%$1.7B
SPINRAZA
16.1%$1.5B
Fumarate
14.8%$1.4B
Interferon
9.8%$946M

AMGN vs BIIB — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLAMGNLAGGINGBIIB

Income & Cash Flow (Last 12 Months)

AMGN leads this category, winning 5 of 6 comparable metrics.

AMGN is the larger business by revenue, generating $38.9B annually — 3.8x BIIB's $10.3B. AMGN is the more profitable business, keeping 24.1% of every revenue dollar as net income compared to BIIB's 3.4%. On growth, BIIB holds the edge at +14.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricAMGN logoAMGNAmgen Inc.BIIB logoBIIBBiogen Inc.
RevenueTrailing 12 months$38.9B$10.3B
EBITDAEarnings before interest/tax$18.3B$1.7B
Net IncomeAfter-tax profit$9.4B$348M
Free Cash FlowCash after capex$9.6B$2.3B
Gross MarginGross profit ÷ Revenue+74.0%+70.0%
Operating MarginEBIT ÷ Revenue+35.5%+7.6%
Net MarginNet income ÷ Revenue+24.1%+3.4%
FCF MarginFCF ÷ Revenue+24.6%+22.8%
Rev. Growth (YoY)Latest quarter vs prior year+8.5%+14.2%
EPS Growth (YoY)Latest quarter vs prior year+19.4%-104.4%
AMGN leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

Evenly matched — AMGN and BIIB each lead in 3 of 6 comparable metrics.

At 27.2x trailing earnings, AMGN trades at a 74% valuation discount to BIIB's 106.4x P/E. On an enterprise value basis, AMGN's 16.2x EV/EBITDA is more attractive than BIIB's 24.5x.

MetricAMGN logoAMGNAmgen Inc.BIIB logoBIIBBiogen Inc.
Market CapShares × price$252.1B$37.0B
Enterprise ValueMkt cap + debt − cash$297.6B$40.9B
Trailing P/EPrice ÷ TTM EPS27.16x106.38x
Forward P/EPrice ÷ next-FY EPS est.19.88x20.09x
PEG RatioP/E ÷ EPS growth rate9.23x—
EV / EBITDAEnterprise value multiple16.25x24.54x
Price / SalesMarket cap ÷ Revenue6.47x3.59x
Price / BookPrice ÷ Book value/share29.24x2.01x
Price / FCFMarket cap ÷ FCF26.31x15.80x
Evenly matched — AMGN and BIIB each lead in 3 of 6 comparable metrics.

Profitability & Efficiency

AMGN leads this category, winning 6 of 9 comparable metrics.

AMGN delivers a 85.6% return on equity — every $100 of shareholder capital generates $86 in annual profit, vs $2 for BIIB. BIIB carries lower financial leverage with a 0.38x debt-to-equity ratio, signaling a more conservative balance sheet compared to AMGN's 6.31x. On the Piotroski fundamental quality scale (0–9), AMGN scores 7/9 vs BIIB's 5/9, reflecting strong financial health.

MetricAMGN logoAMGNAmgen Inc.BIIB logoBIIBBiogen Inc.
ROE (TTM)Return on equity+85.6%+1.9%
ROA (TTM)Return on assets+10.0%+1.1%
ROICReturn on invested capital+14.8%+6.5%
ROCEReturn on capital employed+16.0%+7.7%
Piotroski ScoreFundamental quality 0–975
Debt / EquityFinancial leverage6.31x0.38x
Net DebtTotal debt minus cash$45.5B$3.9B
Cash & Equiv.Liquid assets$9.1B$3.0B
Total DebtShort + long-term debt$54.6B$6.9B
Interest CoverageEBIT ÷ Interest expense5.19x1.86x
AMGN leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

AMGN leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in AMGN five years ago would be worth $24,182 today (with dividends reinvested), compared to $9,262 for BIIB. Over the past 12 months, BIIB leads with a +55.1% total return vs AMGN's +41.8%. The 3-year compound annual growth rate (CAGR) favors AMGN at 22.9% vs BIIB's 4.0% — a key indicator of consistent wealth creation.

MetricAMGN logoAMGNAmgen Inc.BIIB logoBIIBBiogen Inc.
YTD ReturnYear-to-date+44.9%+40.9%
1-Year ReturnPast 12 months+41.8%+55.1%
3-Year ReturnCumulative with dividends+85.7%+12.5%
5-Year ReturnCumulative with dividends+141.8%-7.4%
10-Year ReturnCumulative with dividends+268.5%-22.1%
CAGR (3Y)Annualised 3-year return+22.9%+4.0%
AMGN leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

Evenly matched — AMGN and BIIB each lead in 1 of 2 comparable metrics.

BIIB is the less volatile stock with a 0.35 beta — it tends to amplify market swings less than AMGN's 0.50 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.

MetricAMGN logoAMGNAmgen Inc.BIIB logoBIIBBiogen Inc.
Beta (5Y)Sensitivity to S&P 5000.50x0.35x
52-Week HighHighest price in past year$483.99$261.00
52-Week LowLowest price in past year$312.39$158.05
% of 52W HighCurrent price vs 52-week peak+96.5%+96.0%
RSI (14)Momentum oscillator 0–10063.859.9
Avg Volume (50D)Average daily shares traded2.9M1.2M
Evenly matched — AMGN and BIIB each lead in 1 of 2 comparable metrics.

Analyst Outlook

AMGN leads this category, winning 1 of 1 comparable metric.

Wall Street rates AMGN as "Buy" and BIIB as "Buy". Consensus price targets imply 1.8% upside for BIIB (target: $255) vs -11.0% for AMGN (target: $416). AMGN is the only dividend payer here at 2.02% yield — a key consideration for income-focused portfolios.

MetricAMGN logoAMGNAmgen Inc.BIIB logoBIIBBiogen Inc.
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$415.58$255.00
# AnalystsCovering analysts4149
Dividend YieldAnnual dividend ÷ price+2.0%—
Dividend StreakConsecutive years of raises150
Dividend / ShareAnnual DPS$9.45—
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%
AMGN leads this category, winning 1 of 1 comparable metric.
Key Takeaway

AMGN leads in 4 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.

Best OverallAmgen Inc. (AMGN)Leads 4 of 6 categories

Custom Comparison: AMGN vs BIIB

Compare on any lens — Growth, Value, Income, or pick from 130+ individual metrics.

View as:

AMGN vs BIIB: Frequently Asked Questions

10 questions · data-driven answers · updated daily

01

Is AMGN or BIIB a better buy right now?

For growth investors, Amgen Inc.

(AMGN) is the stronger pick with 9. 9% revenue growth year-over-year, versus 1. 4% for Biogen Inc. (BIIB). Amgen Inc. (AMGN) offers the better valuation at 27. 2x trailing P/E (19. 9x forward), making it the more compelling value choice. Analysts rate Amgen Inc. (AMGN) a "Buy" — based on 41 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — AMGN or BIIB?

On trailing P/E, Amgen Inc.

(AMGN) is the cheapest at 27. 2x versus Biogen Inc. at 106. 4x. On forward P/E, Amgen Inc. is actually cheaper at 19. 9x.

03

Which is the better long-term investment — AMGN or BIIB?

Over the past 5 years, Amgen Inc.

(AMGN) delivered a total return of +141. 8%, compared to -7. 4% for Biogen Inc. (BIIB). Over 10 years, the gap is even starker: AMGN returned +268. 5% versus BIIB's -22. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — AMGN or BIIB?

By beta (market sensitivity over 5 years), Biogen Inc.

(BIIB) is the lower-risk stock at 0. 35β versus Amgen Inc. 's 0. 50β — meaning AMGN is approximately 42% more volatile than BIIB relative to the S&P 500. On balance sheet safety, Biogen Inc. (BIIB) carries a lower debt/equity ratio of 38% versus 6% for Amgen Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — AMGN or BIIB?

By revenue growth (latest reported year), Amgen Inc.

(AMGN) is pulling ahead at 9. 9% versus 1. 4% for Biogen Inc. (BIIB). On earnings-per-share growth, the picture is similar: Amgen Inc. grew EPS 88. 2% year-over-year, compared to -21. 1% for Biogen Inc.. Over a 3-year CAGR, AMGN leads at 11. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — AMGN or BIIB?

Amgen Inc.

(AMGN) is the more profitable company, earning 21. 0% net margin versus 13. 2% for Biogen Inc. — meaning it keeps 21. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AMGN leads at 29. 1% versus 19. 1% for BIIB. At the gross margin level — before operating expenses — AMGN leads at 70. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is AMGN or BIIB more undervalued right now?

On forward earnings alone, Amgen Inc.

(AMGN) trades at 19. 9x forward P/E versus 20. 1x for Biogen Inc. — 0. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BIIB: 1. 8% to $255. 00.

08

Which pays a better dividend — AMGN or BIIB?

In this comparison, AMGN (2.

0% yield) pays a dividend. BIIB does not pay a meaningful dividend and should not be held primarily for income.

09

Is AMGN or BIIB better for a retirement portfolio?

For long-horizon retirement investors, Amgen Inc.

(AMGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 50), 2. 0% yield, +268. 5% 10Y return). Both have compounded well over 10 years (AMGN: +268. 5%, BIIB: -22. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between AMGN and BIIB?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

AMGN pays a dividend while BIIB does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Financial Data & Software Notice: VCP Scanner is an educational financial research database and stock screening software platform. VCP Scanner does not generate, recommend, or package trade decisions, buy/sell signals, or personalized investment advice. Side-by-side metric comparisons analyze public fundamental data for analytical evaluation. See our Terms of Service and Privacy Policy.